Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Brennan, Alana T ^a,b   Maskew, Mhairi ^b   Ive, Prudence ^b   Shearer, Kate ^b   Long, Lawrence ^b   Sanne, Ian ^a,b,c   Fox, Matthew P ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c RIGHT TO CARE   (South Africa)

Author keywords

Antiretroviral therapy; Drug side effects; Drug toxicities; Regimen durability; Resource limited setting; Single drug substitution

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CREATININE CLEARANCE; DRUG SUBSTITUTION; FEMALE; HEALTH CARE FACILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RESPONSE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; SOUTH AFRICA; YOUNG ADULT;

ANTIRETROVIRAL THERAPY; DRUG SIDE EFFECTS; DRUG TOXICITIES; REGIMEN DURABILITY; RESOURCE-LIMITED SETTING; SINGLE-DRUG SUBSTITUTION;

ADENINE; ADULT; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; ORGANOPHOSPHONATES; SOUTH AFRICA;

EID: 84891504093     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18794     Document Type: Article

References (48)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision. Geneva: World Health Organization; 2010.
2. National Department of Health, Republic of South Africa. National antiretroviral treatment guidelines. Johannesburg, South Africa: Jacana Publishers; 2004.
3. National Department of Health, Republic of South Africa. The South African antiretroviral treatment guidelines. 2010. [cited 2013 Aug 1]. Available from: http://www.doh.gov.za/docs/factsheets/guidelines/art.pdf
4. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS. 2007;21:2293-301.
5. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JMAH, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
6. Domingos H, Cunha RVD, Paniago AMM, Martins DM, Elkhoury EB, Souza ASD. Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Braz J Infect Dis. 2009;13:130-6.
7. van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atté EF, Reid T. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg. 2010;104:148-53.
8. Murphy R, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis. 2007;196(Suppl 3):S449-56.
9. Ait-Mohand H, Bonmarchand M, Guiguet M, Slama L, Marguet F, Behin A, et al. Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. HIV Med. 2008;9:738-46.
10. Cournil A, Coudray M, Kouanfack C, Essomba CN, Tonfack CAD, Biwolé-Sida M, et al. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Antivir Ther. 2010;15:1039-43.
11. World Health Organization. Addendum to 2006 WHO guidelines on antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization; 2007.
12. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.
13. Campaign for Access to Essential Medicines. 2008. Untangling the Web of Antiretroviral Price Reductions, 11th ed. Geneva: Médecins sans Frontières. Available from: http://d2pd3b5abq75bb.cloudfront.net/2012/07/ 16/14/49/04/691/UTW-11-ENG-Jul2008.pdf.
14. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867-75.
15. Bihl G. HIV-related renal disease: a clinical and practical approach in the South African context. SAMJ. 2003:11-14.
16. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070-3.
17. Padilla S, Gutierrez F, Masia M, Canovas V, Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS. 2005;19:421-4.
18. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Sundhiya M, et al. Renal dysfunction with tenofovir disoproxil fumarate containing highly active antiretroviral therapy regimes is not observed more frequently: a cohort and case-control study. JAIDS. 2004;37:1489-95.
19. Brennan A, Evans D, Maskew M, Naicker S, Ive P, Sanne I, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011;25(13):1603-9.
20. Stöhr W, Reid A, Walker AS, Ssali F, Munderi P, Mambule I, et al. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antivir Ther. 2011;16(7):1011-20.
21. Global HIV/AIDS response. Epidemic update and health sector progress towards universal access. Progress report 2011. [cited 2013 Aug 1]. Available from: http://whqlibdoc.who.int/publications/2011/9789241502986-eng.pdf.
22. Meyer-Rath G, Brennan A, Long L, Rosen S, Fox MP. National ART cost model South Africa. Johannesburg, South Africa: Health Economics and Epidemiology Research Office; 2013.
23. Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One. 2013;8(5):64459.
24. Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, et al. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr. 2010;54:63-70.
25. Bygrave H, Ford N, Van Cutsem G, Hilderbrand K, Jouquet G, Goemaere E, et al. Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr. 2011;56:e75-8.
26. Njuguna C, Orrell C, Kaplan R, Bekker LG, Wood R, Lawn SD. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS One. 2013;8(5):63596.
27. Boyle A, Sonecha S, Mandalia S, Nelson M. An investigation into the frequency and reasons why patients switch antiretroviral therapy and which antiretrovirals are commonly implicated in toxicity. 18th Annual Conference of the British HIV Association, abstract, 2012 Oct 28; Birmingham: Journal of the International AIDS Society. 2012;15(Suppl 4):18121.
28. National Department of Health, Republic of South Africa. Circular on new criteria for initiating adults on ART at CD4 count of 350 cells/μl and below. Johannesburg, South Africa: National Department of Health; 2011.
29. Fox MP, Maskew M, Macphail AP, Long L, Brennan AT, Westreich D, et al. Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol. 2013;42:430-9.
30. SAS/STAT® 9.3 User's Guide: The MI Procedure (Chapter). SAS Institute Inc., Cary, NC, USA. Available from: http://support.sas.com/documentation/ onlinedoc/stat/930/mi.pdf
31. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley; 1987.
32. SAS/STAT® 9.3 User's Guide: The MIANALYZE Procedure (Chapter). SAS Institute Inc., Cary, NC, USA. Available from: http://support.sas.com/rnd/app/ papers/mianalyzev802.pdf
33. Phan V, Thai S, Choun K, Lynen L, van Griensven J. Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. PLoS One. 2012;7(1):e30647.
34. Anderson RE, Dunkle LM, Smaldone L, Adler M, Wirtz C, Kriesel D, et al. Bristol-Myers Squibb Co., Pharmaceutical Research Institute, Wallingford, Connecticut. Design and implementation of the d4T parallel-track program. J Infect Dis. 1995;171(Suppl 2):S118-22.
35. McComsey GA, Lo Re V 3rd, O'Riordan M,Walker UA, Lebrecht D, Baron E, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis. 2008;46(8):1290-6.
36. Petersen EA, Ramírez-Ronda CH, Hardy WD, Schwartz R, Sacks HS, Follansbee S, et al. Dose-related activity of d4T in patients infected with human immunodeficiency virus. J Infect Dis. 1995;171(Suppl 2):S131-9.
37. Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, et al. A randomized, dose-finding study with ddI plus d4T versus ddI alone in antiviral-naive, HIV-infected Thai patients. AIDS. 2000;14:1375-82.
38. Hoffmann CJ, Charalambous S, Fielding KL, Innes C, Chaisson RE, Grant AD, et al. HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa. AIDS. 2009;23(13):1784-6.
39. van Oosterhout JJ, Mallewa J, Kaunda S, Chagoma N, Njalale Y, Kampira E, Mukaka M, Heyderman RS. Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS One. 2012;7(7):e42029.
40. Maskew M, Westreich D, Fox MP, Maotoe T, Sanne IM. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. J Int AIDS Soc. 2012;15(1):13.
41. Hurwitz SJ, Schinazi RF. In silico study supports the efficacy of a reduced dose regimen for stavudine. Antiviral Res. 2011;92(2):372-7.
42. Mossdorf E, Stoeckle M, Mwaigomole EG, Chiweka E, Kibatala PL, Geubbels E, et al. Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infect Dis. 2011;11:98.
43. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 2007;59:342-6.
44. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet. 2004;363:1253-63.
45. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191:825-9.
46. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS. 2005;19:185-92.
47. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27:1403-12.
48. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther. 2007;12(5):753-60. Development Development Development